Related Experiment Videos
[Hormone receptor system]
1Second Department of Surgery, Nagoya City University, Medical School, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 1988
Summary
Hormonal therapy for advanced breast cancer targets estrogen receptors (ER). Combined chemoendocrine therapy is recommended over exclusive hormonal treatment for better patient outcomes.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Context:
- Estrogen receptor (ER) expression is crucial in normal breast tissue, hyperplastic adenosis, and breast cancer.
- ER-positive breast cancer cells exhibit ER staining throughout most of the cell cycle.
- Estrogen-dependent breast cancer growth is mediated by the ER system.
Purpose:
- To discuss the expression, structure, and function of ER.
- To elucidate the mechanism of hormonal treatments for breast cancer.
- To establish the rationale for hormonal therapy in advanced or recurrent breast cancer.
Summary:
- ER expression is observed in hyperplastic adenosis and cancer, but not normal breast epithelial cells.
- Hormonal therapy interferes with ER function, stabilizing sensitive cells in the G0-G1 phase.
- Chemoendocrine therapy is preferred for advanced/recurrent breast cancer, with "missile therapy" as a potential future approach.
Impact:
- Hormonal therapy has limited efficacy as a standalone treatment for advanced breast cancer.
- Concomitant chemoendocrine therapy is the preferred treatment strategy.
- Further research into drug combinations and targeted therapies like "missile therapy" is warranted.